219 results on '"Heitjan, Daniel F."'
Search Results
2. Predicting Hospital Readmission in Medicaid Patients With COPD Using Administrative and Claims Data
3. Electronic phenotypes to distinguish clinician attention to high body mass index, hypertension, lipid disorders, fatty liver and diabetes in pediatric primary care: Diagnostic accuracy of electronic phenotypes compared to masked comprehensive chart review
4. Supplementary Figure Legends from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
5. Data from CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
6. Supplementary Figure Legend from CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
7. Supplementary Table 2 from Modeling of the Growth Kinetics of Occult Breast Tumors: Role in Interpretation of Studies of Prevention and Menopausal Hormone Therapy
8. Supplemental Table 1 from CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
9. Supplemental Figure 1 from CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
10. Supplementary Methods from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
11. Related Article from Biology, Models, and the Analysis of Tumor Xenograft Experiments
12. Supplemental Tables from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
13. Supplementary Table 1 from Modeling of the Growth Kinetics of Occult Breast Tumors: Role in Interpretation of Studies of Prevention and Menopausal Hormone Therapy
14. Supplemental Figure 2 from CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
15. Related Article from Biology, Models, and the Analysis of Tumor Xenograft Experiments
16. Supplementary Figure 1 from Modeling of the Growth Kinetics of Occult Breast Tumors: Role in Interpretation of Studies of Prevention and Menopausal Hormone Therapy
17. Supplementary Figure 1 from Modeling of the Growth Kinetics of Occult Breast Tumors: Role in Interpretation of Studies of Prevention and Menopausal Hormone Therapy
18. Supplementary Figures from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
19. Supplementary Table 1 from Modeling of the Growth Kinetics of Occult Breast Tumors: Role in Interpretation of Studies of Prevention and Menopausal Hormone Therapy
20. Supplementary Methods from Modeling of the Growth Kinetics of Occult Breast Tumors: Role in Interpretation of Studies of Prevention and Menopausal Hormone Therapy
21. Supplementary Table 2 from Modeling of the Growth Kinetics of Occult Breast Tumors: Role in Interpretation of Studies of Prevention and Menopausal Hormone Therapy
22. Supplementary Methods from Modeling of the Growth Kinetics of Occult Breast Tumors: Role in Interpretation of Studies of Prevention and Menopausal Hormone Therapy
23. Survival of cancer survivors with a new pancreatic cancer diagnosis
24. PSA-Net: Deep learning–based physician style–aware segmentation network for postoperative prostate cancer clinical target volumes
25. Estimating the optimal timing of surgery by imputing potential outcomes
26. Analysis of local sensitivity to nonignorability with missing outcomes and predictors
27. Generalizing Clinical Trial Results to a Target Population
28. Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer
29. COVID-19 associated mortality and cardiovascular disease outcomes among US women veterans
30. Survival of women diagnosed with breast cancer and who have survived a previous cancer
31. Approach to Managing a Postmenopausal Patient
32. Editorial: Clinical trial design in the era of COVID-19
33. Estimating the optimal timing of surgery from observational data
34. Flexible, rule-based dose escalation: The cohort-sequence design
35. Underlying Breast Cancer Risk and Menopausal Hormone Therapy
36. COVID-19 Associated Mortality and Cardiovascular Disease Outcomes Among U.S. Women Veterans
37. Sensitivity to Nonignorability in Frequentist Inference
38. Statistical modeling and prediction of clinical trial recruitment
39. Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin
40. Measuring the Impact of Nonignorable Missingness Using the R Package isni
41. Glucocorticoid Receptor Mutations and Hypersensitivity to Endogenous and Exogenous Glucocorticoids
42. Statistical justification of expansion cohorts in phase 1 cancer trials
43. Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers
44. Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders
45. Adaptive parametric prediction of event times in clinical trials
46. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer
47. Coarse Data
48. Cure modeling in real-time prediction: How much does it help?
49. Commentary on Mason et al.
50. Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.